Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Rebuzzi SE, et al. Among authors: prelaj a. Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. Int J Mol Sci. 2021. PMID: 33807876 Free PMC article. Review.
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D. Prelaj A, et al. Clin Lung Cancer. 2020 Jul;21(4):365-377.e5. doi: 10.1016/j.cllc.2019.11.017. Epub 2020 Mar 7. Clin Lung Cancer. 2020. PMID: 32245624 Clinical Trial.
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.
Rebuzzi SE, Prelaj A, Friedlaender A, Cortellini A, Addeo A, Genova C, Naqash AR, Auclin E, Mezquita L, Banna GL. Rebuzzi SE, et al. Among authors: prelaj a. Crit Rev Oncol Hematol. 2022 Nov;179:103806. doi: 10.1016/j.critrevonc.2022.103806. Epub 2022 Sep 8. Crit Rev Oncol Hematol. 2022. PMID: 36087850 Review.
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Banna GL, Friedlaender A, Tagliamento M, Mollica V, Cortellini A, Rebuzzi SE, Prelaj A, Naqash AR, Auclin E, Garetto L, Mezquita L, Addeo A. Banna GL, et al. Among authors: prelaj a. Curr Oncol Rep. 2022 Dec;24(12):1851-1862. doi: 10.1007/s11912-022-01335-8. Epub 2022 Oct 18. Curr Oncol Rep. 2022. PMID: 36255605 Review.
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Prelaj A, et al. Cancers (Basel). 2021 Mar 15;13(6):1300. doi: 10.3390/cancers13061300. Cancers (Basel). 2021. PMID: 33803958 Free PMC article. Review.
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. Prelaj A, et al. Cancers (Basel). 2019 Dec 5;11(12):1954. doi: 10.3390/cancers11121954. Cancers (Basel). 2019. PMID: 31817541 Free PMC article.
72 results